109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
NOVEL TLR9 AGONISTS
#902COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#903TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#904ANTIVIRAL SILENCING RNA MOLECULES, CHEMICALLY MODIFIED ANTIVIRAL SILENCING RNA MOLECULES WITH ENHANCED CELL PENETRATING ABILITIES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF FOR TREATMENT OF VIRAL INFECTIONS
#905Compositions for modulating tau expression
#906RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
#907UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
#908Modulators of PCSK9 Expression
#909NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#910COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME
#911METHOD FOR ACTIVATING EXPRESSION OF GAMMA-GLOBIN GENE, AND COMPOSITION
#912POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#913Modified oligonucleotides
#914TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
#915Oligonucleotides for inducing paternal UBE3A expression
#916MICRORNAS AND METHODS OF THEIR USE
#917GalNAc compositions for improving siRNA bioavailability
#918ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#919OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#920METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
#921METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL)
#922G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#923COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION
#924RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION
#925Tuning cascade assay kinetics via molecular design
#926Oligonucleotide Agonists Targeting Progranulin
#927OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#928Modified guide RNAs
#929NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY
#930RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF
#931COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF
#932Compositions and methods for modulating APOC3 expression
#933ADAR DEPENDENT EDITING COMPOSITIONS AND METHODS OF USE THEREOF
#934COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A
#935siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
#936METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1)
#937COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES
#938METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1)
#939METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2)
#940Muscle targeting complexes and uses thereof for treating dystrophinopathies
#941Compositions and methods for targeting, editing, or modifying genes
#942THERAPEUTICS FOR SYNGAP HAPLOINSUFFICIENCY
#943Modulators of APOL1 expression
#944Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#945MODULATION OF FACTOR 11 EXPRESSION
#946PRODUCTS AND COMPOSITIONS
#947METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE SYNTHETASE (ASS1)
#948SIRNA OF ANGPTL3 AND USE THEREOF
#949Circular siRNAs
#950Compositions and methods for inhibiting expression of transthyretin
#951COMPOSITIONS AND METHODS FOR ENHANCING REVERSE TRANSCRIPTASE ACTIVITY AND/OR REDUCING THE INHIBITION OF REVERSE TRANSCRIPTASE
#952Nucleic acid oligomers and uses therefor
#953PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
#954OPA1 antisense oligomers for treatment of conditions and diseases
#955GENOME EDITING OF HUMAN NEURAL STEM CELLS USING NUCLEASES
#956CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE
#957METHOD AND DRUG FOR TREATING HURLER SYNDROME
#958STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE
#959METHODS AND COMPOSITIONS FOR NEUROPROTECTION
#960Compositions of matter for detection assays
#961Compositions and methods for targeting, editing, or modifying genes
#962TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS
#963COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
#964CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE
#965ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR)
#966Compounds and Methods for Reducing ATXN3 Expression
#967RNA EDITING INHIBITORS AND METHODS OF USE
#968Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof
#969METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#970NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF
#971OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#972COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME
#973INHIBITION OF POLYOMAVIRUS REPLICATION
#974MAPT RNA INTERFERENCE AGENTS
#975Guanosine Analogues for Use in Therapeutics Polynucleotides
#976METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF)
#977THERAPEUTICS FOR HAPLOINSUFFICIENCY CONDITIONS
#978METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#979SINGLE-STRANDED OLIGONUCLEOTIDE
#980SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION
#981DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR TREATING COVID-19 CONTAINING SAME
#982MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#983DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO
#984MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#985Compositions and methods of treating muscle atrophy and myotonic dystrophy
#986Compositions and methods of treating muscle atrophy and myotonic dystrophy
#987MODULATORS OF FOXP3 EXPRESSION
#988CYTOTOXIC T-LYMPHOCYTE BINDING APTAMERS
#989BISPECIFIC PERSONALIZED APTAMERS
#990TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#991OLIGONUCLEOTIDES FOR SOD1 MODULATION
#992NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#993Tuning cascade assay kinetics via molecular design
#994APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#995USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#996Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#997PD-1-specific antisense oligonucleotide and its use in therapy
#998COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT
#999Compositions and Methods for Modulation of SMN2 Splicing in a Subject
#1000Reducing intron retention
#1001USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1002Compositions and Methods for Genome Editing
#1003Immunostimulatory compositions
#1004Methods and Compositions for the ADAR-Mediated Editing of ABCA4
#1005Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#1006COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SYNGAP1
#1007METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA
#1008COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#1009Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
#1010COMPOUNDS AND METHODS FOR REDUCING PSD3 EXPRESSION
#1011CPG ODN HAVING IMMUNOREGULARTORY FUNCTION AND USE THEREOF
#1012COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSION
#1013MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
#1014Base editing of PCSK9 and methods of using same for treatment of disease
#1015ANTISENSE OLIGONUCLEOTIDE OF CALM2
#1016PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR
#1017CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
#1018Prekallikrein-modulating compositions and methods of use thereof
#1019COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION
#1020COMPOSITIONS AND METHODS OF INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
#1021COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1022NUCLEIC ACID COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
#1023ANTISENSE NUCLEIC ACIDS
#1024COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PREKALLIKREIN-ASSOCIATED CONDITIONS
#1025DESIGN METHOD FOR OPTIMIZED RIG-I LIGANDS
#1026MODULATORS OF GROWTH HORMONE RECEPTOR
#1027OXIDIZED TUMOR CELL LYSATES ENCAPSULATED IN LIPOSOMAL SPHERICAL NUCLEIC ACIDS AS POTENT CANCER IMMUNOTHERAPEUTICS
#1028OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#1029FORMULATIONS
#1030SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof
#1031ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1032COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION
#1033COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#1034PRODUCTS AND COMPOSITIONS
#1035ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROME
#1036CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS12B
#1037ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1038ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1039DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF
#1040OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES
#1041EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#1042Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1043LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1044MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1045RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
#1046UNC13A antisense oligonucleotides
#1047COMPOUNDS AND METHODS FOR MODULATING KCNQ2
#1048USP10 TARGETED SELF-DELIVERABLE SIRNA COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING FIBROSIS AND/OR SCARRING
#1049USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1050CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS
#1051Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#1052COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
#1053USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1054COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#1055USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1056MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY
#1057COMPOUNDS AND METHODS FOR MODULATING SPLICING OF PRE-MRNA
#1058ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1059Compounds and methods for reducing LRRK2 expression
#1060HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1061Oligomeric compounds for reducing DMPK expression
#1062Selective Antisense Compounds and Uses Thereof
#1063Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#1064Compositions for Modulating C9ORF72 Expression
#1065Transthyretin (TTR) iRNA compositions and methods of use thereof
#1066Compositions for treatment of polycystic kidney disease
#1067METHODS FOR REDUCING HTT EXPRESSION
#1068COMPOSITIONS AND METHODS FOR INHIBITING ALPHA-1 ANTITRYPSIN EXPRESSION
#1069METHODS OF TREATING SPINAL MUSCULAR ATROPHY
#1070CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY
#1071PRODRUG INCORPORATED sgRNA SYNTHESIS
#1072RNA-Editing Oligonucleotides and Uses Thereof
#1073METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#1074KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1075USE OF MIRNA-485 INHIBITORS FOR TREATING TAUOPATHY
#1076MICRORNA COMPOSITIONS AND METHODS OF USE
#1077COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#1078ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#1079SYNTHETIC AGONISTS OF DNA-PK AND THEIR USE
#1080STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1081COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSING OF METHYLATION-CONTROLLED J-PROTEIN (MCJ)
#1082Guide RNAs with chemical modification for prime editing
#1083Compositions and methods of treating facioscapulohumeral muscular dystrophy
#1084Compositions of matter for detection assays
#1085PRODUCTS AND COMPOSITIONS
#1086CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY
#1087COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION
#1088MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE
#1089Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#1090RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
#1091TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
#1092POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION
#1093Nucleic acid vaccination using neo-epitope encoding constructs
#1094Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#1095APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1096Modified compounds and uses thereof
#1097ANTAGONISM AS A THERAPY FOR TDP-43 PROTEINOPATHIES
#1098ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
#1099UNIVERSAL DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
#1100STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO
#1101NEW METHOD FOR TARGETED EDITING OF RNA
#1102Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
#1103Compositions and methods for modulating complement factor B expression
#1104METHODS AND COMPOSITIONS FOR THE INHIBITION OF HEPATITIS B AND HEPATITIS D VIRUS INFECTIONS
#1105ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1106COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#1107Antisense Oligonucleotides Targeting ATXN3
#1108COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#1109MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
#1110Polynucleotide compositions and methods for gene expression regulations
#1111Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#1112Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
#1113COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#1114Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
#1115METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXAPNSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY
#1116ANTI-SLC6A1 OLIGONUCLEOTIDES AND RELATED METHODS
#1117COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION
#1118Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
#1119Compositions and methods for treating cancer
#1120Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof
#1121SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
#1122RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
#1123Tunable Reversir™ compounds
#1124MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#1125Implantable Medical Device for the Delivery of a Nucleic Acid
#1126COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1127Compounds and methods for reducing IFNAR1 expression
#1128Nucleic acids for inhibiting expression of C3 in a cell
#1129Modulation of huntingtin expression
#1130IDENTIFYING NON-PRODUCTIVE SPLICE SITES
#1131Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
#1132Oligonucleotides for SARS-CoV-2 modulation
#1133COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS
#1134Nucleic acids for inhibiting expression of PROS1 in a cell
#1135EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS
#1136Modulators and modulation of the receptor for advanced glycation end-products RNA
#1137RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
#1138RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
#1139PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1140Compounds and methods for modulating factor XII
#1141IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
#1142Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
#1143RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
#1144CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY
#1145Selective antisense compounds and uses thereof
#1146OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#1147Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1148METHODS FOR TREATING HEPATITIS B INFECTION
#1149PIKFYVE antisense oligonucleotides
#1150XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1151COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
#1152Compounds and methods for modulating UBE3A-ATS
#1153Compositions and methods of treating muscle dystrophy
#1154Modulation of Angiopoietin-Like 3 Expression
#1155MODULATING GENOMIC COMPLEXES
#1156Selective reduction of allelic variants
#1157COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1158COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1159MODIFIED iRNA AGENTS
#1160COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
#1161REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF
#1162OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF
#1163THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
#1164NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#1165LAG3 binding peptides
#1166COMPOSITIONS AND METHODS FOR SILENCING UGT1A1 GENE EXPRESSION
#1167Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
#1168RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#1169CRISPR COMPLEX-BASED DETECTION SYSTEM AND METHOD
#1170Organic compositions to treat HSF1-related diseases
#1171ASYMMETRIC SIRNA INHIBITING EXPRESSION OF PD-1
#1172COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#1173RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#1174Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
#1175SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1176Transglutaminase-mediated conjugation
#1177HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1178OLIGONUCLEOTIDE-BASED THERAPY FOR ULCERATIVE COLITIS
#1179PPM1A INHIBITORS AND METHODS OF USING SAME
#1180COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
#1181Modified Guide RNAs for Gene Editing
#1182Modified antisense oligonucleotide for inhibition of FoxP3 expression
#1183Dynamic pharmacokinetic-modifying anchors
#1184FN3 domain-siRNA conjugates and uses thereof
#1185OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
#1186Compositions and methods for modulating PNPLA3 expression
#1187Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
#1188CD44 aptamer
#1189COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1190ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
#1191ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
#1192PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1193COMPOSITION FOR DIAGNOSIS OR TREATMENT OF A CONDITION ASSOCIATED WITH INCREASED ACTIVITY OF EIF4E COMPRISING AN EIF4E INHIBITOR
#1194GNAQ targeted dsRNA compositions and methods for inhibiting expression
#1195COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
#1196OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES
#1197TARGETING RLIM TO MODULATE BODY WEIGHT AND OBESITY
#1198CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR RNA EDITING
#1199COMPOSITIONS AND METHODS FOR CD123 MODIFICATION
#1200OLIGONUCLEOTIDES AND METHODS OF USE FOR TREATING NEUROLOGICAL DISEASES